Laxative Ingredient Pediatric Study Provides Compass For FDA Action
This article was originally published in The Tan Sheet
FDA supports research to evaluate long-term exposure of polyethylene glycol 3350 in children, saying “pharmacokinetic data from pediatric patients would provide better information” on the ingredient’s safety. A consumer group that petitioned FDA for a black box warning has additional questions.
You may also be interested in...
A consumer group petitions FDA for a black box warning on Merck’s MiraLAX and generic equivalents, citing the potential for adverse reactions in children. Gastroenterologists largely have not seen such risks from off-label pediatric use of the OTC laxative.
At least one FTC commissioner seems convinced that the agency’s Enforcement Guides are ripe for an update to address unscrupulous influencer marketing practices. Democrat Rohit Chopra proposes their codification into formal rules that would make violators liable for civil penalties and damages.